araag2/HINT huggingface dataset:
Clinical trial NCT02091375 (phase 3, status: completed)
Conditions: epilepsy, dravet syndrome
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.833, G40.834
Drugs: gwp42003-p 20 mg/kg/day dose, placebo control
SMILES: CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participants were male or female aged between 2 and 18 years (inclusive).

          -  Participants had a documented history of Dravet Syndrome that was not completely
             controlled by current antiepileptic drugs.

          -  Participants took one or more antiepileptic drugs at a dose that had been stable for
             at least four weeks.

          -  All medications or interventions for epilepsy (including ketogenic diet and vagus
             nerve stimulation) were stable for four weeks prior to screening and participants were
             willing to maintain a stable regimen throughout the study.

        Key Exclusion Criteria:

          -  Participants had clinically significant unstable medical conditions other than
             epilepsy.

          -  Participants had clinically relevant symptoms or a clinically significant illness in
             the four weeks prior to screening or randomization, other than epilepsy.

          -  Participants were currently using or had in the past used recreational or medicinal
             cannabis or synthetic cannabinoid based medications (including Sativex®) within the
             three months prior to study entry and were unwilling to abstain for the duration for
             the study.

          -  Participants had any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the investigational medicinal products.

          -  Participants had been part of a previous clinical trial involving another
             investigational product in the previous six months.

          -  There were plans for the participants to travel outside their country of residence
             during the study.

          -  Participants previously randomized into this study. In particular, participants who
             participated in Part A of the study could not enter Part B.
Clinical trial NCT02091739 (phase 3, status: completed)
Conditions: chronic troublesome sialorrhea, parkinson's disease, post-stroke, traumatic brain injury
ICD codes: G20, Z87.820, Z13.850, S06.2X0S, S06.2X0A, S06.2X0D, S06.300S, S06.300A
Drugs: incobotulinumtoxina (100 units), incobotulinumtoxina (75 units), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented diagnosis of the basic neurological condition associated with sialorrhea
             (as above, (i), (ii) or (iii); with onset at least 6 months before screening).

          -  Chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain
             injury (for at least 3 months) at screening, defined as the presence of all of the
             following, at screening and at baseline and for at least the 3 months before screening
             (where retrospective response to questionnaires is impossible, a statement of
             equivalent severity will suffice):

               1. A Drooling Severity and Frequency Scale [DSFS] sum score of at least 6 points and

               2. A score of at least 2 points for each item of the DSFS and

               3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for
                  Parkinson's Disease [mROMP], Section 'III Drooling', Item A).

          -  A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and
             a score of at most 3 points on Item C), at screening and at baseline.

        Exclusion Criteria:

          -  Non-neurological secondary causes of sialorrhea.

          -  Unstable concomitant medication influencing sialorrhea (such as anticholinergics for
             the treatment of parkinsonism; dosages of these medications must have been stable for
             at least 4 weeks before study entry, i.e. screening, and must be planned to remain
             stable during the course of the study.

          -  Recent (i.e., four weeks) drug treatment for sialorrhea.

          -  History of recurrent aspiration pneumonia.

          -  Extremely poor dental/oral condition as assessed by a qualified dentist.

          -  Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with
             - or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any
             ingredient of the study preparation.

          -  Recent (i.e., four weeks) changes in anti-parkinsonian medication.

          -  Previous or planned surgery or irradiation to control sialorrhea.
Clinical trial NCT02091986 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: symbicort pmdi, symbicort pmdi
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Has a documented clinical diagnosis of asthma defined by the ATS for at least 6 months
             prior to Visit 2

          -  Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the last
             dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of 60% to
             100% of predicted normal

          -  Demonstrated reversibility of clinic FEV1 of ≥12% from pre -albuterol/salbutamol level
             within 15 to 30 minutes after administration of a standard dose of
             albuterol/salbutamol.

        Exclusion Criteria:

          -  Have been hospitalized at least once or required emergency treatment more than once
             for an asthma-related condition during the 6 months prior to Visit 1

          -  Have required treatment with systemic corticosteroids (eg, oral, parenteral, or
             rectal) for any reason within the 6 weeks prior to Visit 1
Clinical trial NCT02096705 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: dapagliflozin, dapagliflozin placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c
             ≥ 7.5% and ≤ 11.0% obtained at screening visit

          -  Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at
             least 8 weeks prior to enrollment

        Inclusion criteria for randomization:

        HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

        Exclusion Criteria:

          -  Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of
             Enrollment

          -  History of diabetic ketoacidosis of hyperosmolar nonketotic coma

          -  Clinically diagnosed Type 1 diabetes mellitus

          -  Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV

          -  Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg
             and/or diastolic blood pressure (DBP) ≥ 110 mmHg

          -  History of unstable or rapidly progressing renal disease

          -  History of severe hepatobiliary disease

          -  Mallingancy within 5 years of the screening/enrollment visit
Clinical trial NCT02098395 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: liraglutide, liraglutide, liraglutide, placebo, placebo, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male or female, aged equal to or greater than 18 years at the time of signing informed
             consent

          -  Type 1 diabetes mellitus (as diagnosed clinically) 12 months or longer prior to Visit
             1 (i.e. screening)

          -  Treatment with basal bolus or CSII (continuous subcutaneous insulin infusion, insulin
             pump) treatment 6 months or longer prior to Visit 1 (i.e. screening)

          -  Stable insulin treatment 3 months or longer prior to Visit 1 (i.e. screening), as
             judged and documented by the investigator

          -  HbA1c 7.0-10.0 percent (Diabetes Control and Complications Trial (DCCT)), both
             inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53-86
             mmol/mol (International Federation of Clinical Chemistry (IFCC))

        Exclusion Criteria:

          -  Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase
             IV (DPPIV) inhibitors

          -  Use of any medication, which in the investigator's opinion could interfere with the
             glycaemic control (e.g. systemic corticosteroids, pramlintide (Symlin®)) or affect the
             subject's safety. Premix insulin is not allowed

          -  Known proliferative retinopathy or maculopathy requiring acute treatment

          -  Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged
             by the investigator

          -  Uncontrolled/untreated blood pressure at screening (Visit 1) (after resting for 5
             minutes) while sitting greater than 160 mmHg for systolic or greater than 100 mmHg for
             diastolic (repeated measurement at Visit 2 (prior to performing the trial related
             activities) is allowed to exclude white-coat hypertension)

          -  History of acute or chronic pancreatitis

          -  Screening (Visit 1) calcitonin value equal to or greater than 50 ng/L
Clinical trial NCT02104804 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin 5mg, placebo for saxagliptin
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Provision of informed consent before participating in the study.

          2. Diagnosed with type 2 diabetes.

          3. Inadequate glycemic control (screening: HbA1c ≥7.5% and ≤11.0% and FPG<270 mg/dL
             (15mmol/L). At Day -4 visit, HbA1c ≥7.5% and ≤10.5%. and FPG<270 mg/dL (15mmol/L)).

          4. On a stable dose of insulin for 8 weeks or longer prior to screening.

          5. If taking metformin, subjects should have been taking the same daily dose for 8 weeks
             or longer prior to screening.

          6. Insulin type should be intermediate-acting or long-acting (basal) or premixed
             (premixed formulation may include short- or rapid-acting insulin as one component).

          7. Body mass index ≤45 kg/m^2.

        Exclusion Criteria:

          1. Women of childbearing potential unable or unwilling to use acceptable birth control.

          2. Women who are pregnant or breastfeeding.

          3. Symptoms of poorly controlled diabetes. including but not limited to, marked polyuria
             and polydipsia with greater than 10% weight loss during the last three months prior to
             screening or other signs and symptoms.

          4. Significant cardiovascular history defined as: myocardial infarction, coronary
             angioplasty or bypass graft, valvular disease or repair, unstable clinical significant
             arrhythmia, unstable angina pectoris, transient ischemic attack, or cerebrovascular
             accident.

          5. Congestive heart failure

          6. Chronic or repeated intermittent corticosteroid treatment (subjects receiving stable
             doses of replacement corticosteroid (except dexamethasone) therapy may be enrolled).

          7. History of unstable or rapidly progressing renal disease.

          8. History of alcohol or drug abuse within the previous year.

          9. Unstable major psychiatric disorders.

         10. History of hemoglobinopathies

         11. Immunocompromised status

         12. Severe liver disease.

         13. In subjects treated with insulin alone a calculated creatinine clearance <50 ml/min.
             In patients treated with insulin in combination with metformin a calculated creatinine
             clearance <60 ml/min or serum creatinine > 1.5 mg/dL in males or > 1.4mg/dL in
             females.

         14. Anemia
Clinical trial NCT02105636 (phase 3, status: active, not recruiting)
Conditions: squamous cell carcinoma of the head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: nivolumab, cetuximab, methotrexate, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG)
             performance status ≤ 1

          -  Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx),
             stage III/IV and not amenable to local therapy with curative intent (surgery or
             radiation therapy with or without chemotherapy)

          -  Tumor progression or recurrence within 6 months of last dose of platinum therapy in
             the adjuvant (ie with radiation after surgery), primary (ie, with radiation),
             recurrent, or metastatic setting

          -  Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per
             Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria

        Exclusion Criteria:

          -  Active brain metastases or leptomeningeal metastases are not allowed

          -  Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx,
             squamous cell carcinoma of unknown primary, and salivary gland or non-squamous
             histologies (eg: mucosal melanoma) are not allowed

          -  Subjects with active, known or suspected autoimmune disease
Clinical trial NCT02106546 (phase 3, status: completed)
Conditions: squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, veliparib, paclitaxel, placebo to veliparib
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Life expectancy > 12 weeks

          2. Subject must have cytologically or histologically confirmed squamous NSCLC.

          3. Subject must have advanced or metastatic squamous NSCLC that is not amenable to
             surgical resection or radiation with curative intent at time of study Screening.

          4. Subjects with recurrent squamous NSCLC after surgical treatment that is not amenable
             to surgical resection or radiation with curative intent are eligible.

          5. Subject must have at least 1 unidimensional measurable NSCLC lesion on a computerized
             tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors
             (RECIST - version 1.1).

        Exclusion Criteria:

          1. Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with
             polyethoxylated castor oil (Cremophor).

          2. Subject has a known hypersensitivity to platinum compounds.

          3. Subject has peripheral neuropathy >= grade 2.

          4. Subject has non-squamous NSCLC, or a known epidermal growth factor receptor (EGFR)
             mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic
             lymphoma kinase (ALK) gene rearrangement.

          5. Subject has received prior cytotoxic chemotherapy (including definitive
             chemoradiotherapy) for NSCLC, except for adjuvant or neoadjuvant therapy.
Clinical trial NCT02106832 (phase 3, status: completed)
Conditions: bronchiectasis
ICD codes: J47.9, Q33.4, J47.1, J47.0
Drugs: ciprofloxacin (bayq3939) dry powder for inhalation, ciprofloxacin (bayq3939) dry powder for inhalation, placebo, placebo
SMILES: OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a proven and documented diagnosis of non CF idiopathic or post
             infectious bronchiectasis

          -  Stable pulmonary status and stable regimen of standard treatment at least for the past
             4 weeks

        Exclusion Criteria:

          -  Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted

          -  Active allergic bronchopulmonary aspergillosis

          -  Active and actively treated non tuberculosis mycobacterial (NTM) infection or
             tuberculosis

          -  Primary diagnosis of Chronic obstructive pulmonary disease (COPD)
Clinical trial NCT02107898 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: placebo (for alirocumab), alirocumab, lipid-modifying therapy (lmt)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        Participants with heterozygous familial hypercholesterolemia or non-familial
        hypercholesterolemia who were not adequately controlled with a stable daily dose of statin
        with or without other lipid modifying therapy, at stable dose prior to the screening visit
        (Week -3).

        Exclusion criteria:

          1. LDL-C <100 mg/dL (<2.59 mmol/L) at the screening visit in participants with
             heterozygous familial hypercholesterolemia or in participants with non-familial
             hypercholesterolemia who had a history of documented coronary heart disease as
             described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of
             Atherosclerotic Cardiovascular Diseases 2012.

          2. LDL-C <120 mg/dL (<3.10 mmol/L) at the screening visit in participants with
             non-familial hypercholesterolemia who had a history of documented diseases or other
             risk factors as categorized in primary prevention category III as described in JAS
             Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.

          3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4
             weeks prior to the screening visit or between screening and randomization visits.

          4. Age <20 years at the screening visit.

        The above information is not intended to contain all considerations relevant to a
        participants' potential participation in a clinical trial.
Clinical trial NCT02108366 (phase 3, status: completed)
Conditions: influenza, human
ICD codes: J11.81, J11.82, J10.01, J10.81, J10.82, J11.08, J11.2
Drugs: celecoxib, oseltamivir, placebo
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        1) Male or female patients ≥18 years 2) Written informed consent by patient or next-of kin
        (if patient is too ill to consent) 3) Presumptive diagnosis of influenza A satisfying both
        clinical and laboratory criteria. The laboratory criteria are defined as at least one
        RT-PCR positive for influenza A (H1N1, H3N2, H5N1 and H7N9) from respiratory clinical
        specimens including nasopharyngeal samples and endotracheal aspirates. The clinical
        criteria are defined as hospitalization with fever or one of the symptoms suggestive of
        influenza infection including sore throat, rhinorrhea, cough or shortness of breath 2)
        Desaturation to <90% in room air by pulse oximetry and required oxygen supplement 3) Within
        7 days of onset of symptoms. Patients have to fulfil all the aforementioned criteria.

        Exclusion Criteria:

        1) Age <18 years. 2) A known hypersensitivity to celecoxib, oseltamivir or zanamivir 3)
        Unable to obtain informed consents 4) Influenza A infection diagnosed beyond 7 days from
        symptom onset 5) Patients receiving other antiviral treatment (apart from oseltamivir or
        zanamivir), N-acetylcystiene, statins and tradition Chinese medicine during the current
        admission 6) Patients with renal impairment of creatinine clearance < 30mL/min
Clinical trial NCT02109562 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: rbp-7000, placebo, risperidone
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between the ages of 18 to 55 years, inclusive

          -  Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual, Edition 4,
             text revision (DSM-IV-TR) criteria

          -  Subjects who are deemed "valid" by the State, Assessability, Face, Ecological, and
             Rule (SAFER) interview

          -  Subjects who are otherwise healthy on the basis of their physical examination

        Exclusion Criteria:

          -  Subjects who have an improvement in their total Positive and Negative Syndrome Scale
             (PANSS) score of 20% or greater between the initial screening visit and the first day
             of treatment.

          -  Subjects taking daily oral risperidone at a dose ≥ 6 mg/day

          -  Subjects who have received a depot antipsychotic within 120 days of screen

          -  Subjects with treatment resistant schizophrenia, as judged by the investigator, who
             have been treated with antipsychotics for adequate durations and with adequate
             dosages.